A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma

C. Sakaguchi, K. Ashida, S. Yano, K. Ohe, Naoko Wada, N. Hasuzawa, yayoi matsuda, Shohei Sakamoto, Ryuichi Sakamoto, Uchi Hiroshi, Masutaka Furue, M. Nomura, Yoshihiro Ogawa

研究成果: ジャーナルへの寄稿記事

抄録

Nivolumab, an anti-PD-1 antibody, is now considered an important therapeutic agent in several advanced malignancies. However, immune-related adverse events such as endocrinopathies have been reported with its use. Thyroid disorder and isolated adrenocorticotropic hormone deficiency have frequently been reported as nivolumab-induced immune-related adverse events. Another endocrinopathy is nivolumab-induced type 1 diabetes mellitus (t1dm), described as diabetes mellitus with rapid onset and complete insulin insufficiency, at times leading to fulminant t1dm. We report the case of a 68-year-old woman who developed pancreatic islet-related autoantibody-negative t1dm, possibly induced by nivolumab, under continuous glucocorticoid administration. She was treated with nivolumab for advanced malignant melanoma, concomitant with 10 mg prednisolone daily for thrombophlebitis tapered to 5 mg after 13 courses of nivolumab therapy. At approximately the 27th course of nivolumab therapy, she showed elevated plasma glucose levels despite preserved insulin secretion. A month later, she developed diabetic ketoacidosis. Her insulin secretion decreased and finally was exhausted. She was diagnosed with acute-onset rather than fulminant t1dm because of a rapidly progressive course to diabetic ketoacidosis during just more than 1 week. She is currently receiving insulin replacement. There has been no recurrence of the melanoma. Thus, nivolumab might induce autoimmune diabetes mellitus, with patients having t1dm-sensitive human leucocyte antigen being more susceptible even when receiving glucocorticoids. Physicians should be aware that nivolumab could potentially induce t1dm as a critical immune-related adverse event.

元の言語英語
ページ(範囲)e115-e118
ジャーナルCurrent oncology (Toronto, Ont.)
26
発行部数1
DOI
出版物ステータス出版済み - 2 1 2019

Fingerprint

Type 1 Diabetes Mellitus
Melanoma
Insulin
Diabetic Ketoacidosis
Glucocorticoids
Diabetes Mellitus
nivolumab
Thrombophlebitis
HLA Antigens
Prednisolone
Islets of Langerhans
Autoantibodies
Thyroid Gland
Therapeutics
Physicians
Glucose
Recurrence
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology

これを引用

A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. / Sakaguchi, C.; Ashida, K.; Yano, S.; Ohe, K.; Wada, Naoko; Hasuzawa, N.; matsuda, yayoi; Sakamoto, Shohei; Sakamoto, Ryuichi; Hiroshi, Uchi; Furue, Masutaka; Nomura, M.; Ogawa, Yoshihiro.

:: Current oncology (Toronto, Ont.), 巻 26, 番号 1, 01.02.2019, p. e115-e118.

研究成果: ジャーナルへの寄稿記事

Sakaguchi, C, Ashida, K, Yano, S, Ohe, K, Wada, N, Hasuzawa, N, matsuda, Y, Sakamoto, S, Sakamoto, R, Hiroshi, U, Furue, M, Nomura, M & Ogawa, Y 2019, 'A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma', Current oncology (Toronto, Ont.), 巻. 26, 番号 1, pp. e115-e118. https://doi.org/10.3747/co.26.4130
Sakaguchi C, Ashida K, Yano S, Ohe K, Wada N, Hasuzawa N その他. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. Current oncology (Toronto, Ont.). 2019 2 1;26(1):e115-e118. https://doi.org/10.3747/co.26.4130
Sakaguchi, C. ; Ashida, K. ; Yano, S. ; Ohe, K. ; Wada, Naoko ; Hasuzawa, N. ; matsuda, yayoi ; Sakamoto, Shohei ; Sakamoto, Ryuichi ; Hiroshi, Uchi ; Furue, Masutaka ; Nomura, M. ; Ogawa, Yoshihiro. / A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. :: Current oncology (Toronto, Ont.). 2019 ; 巻 26, 番号 1. pp. e115-e118.
@article{32e5bb9be06446fb9d370f11c8329618,
title = "A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma",
abstract = "Nivolumab, an anti-PD-1 antibody, is now considered an important therapeutic agent in several advanced malignancies. However, immune-related adverse events such as endocrinopathies have been reported with its use. Thyroid disorder and isolated adrenocorticotropic hormone deficiency have frequently been reported as nivolumab-induced immune-related adverse events. Another endocrinopathy is nivolumab-induced type 1 diabetes mellitus (t1dm), described as diabetes mellitus with rapid onset and complete insulin insufficiency, at times leading to fulminant t1dm. We report the case of a 68-year-old woman who developed pancreatic islet-related autoantibody-negative t1dm, possibly induced by nivolumab, under continuous glucocorticoid administration. She was treated with nivolumab for advanced malignant melanoma, concomitant with 10 mg prednisolone daily for thrombophlebitis tapered to 5 mg after 13 courses of nivolumab therapy. At approximately the 27th course of nivolumab therapy, she showed elevated plasma glucose levels despite preserved insulin secretion. A month later, she developed diabetic ketoacidosis. Her insulin secretion decreased and finally was exhausted. She was diagnosed with acute-onset rather than fulminant t1dm because of a rapidly progressive course to diabetic ketoacidosis during just more than 1 week. She is currently receiving insulin replacement. There has been no recurrence of the melanoma. Thus, nivolumab might induce autoimmune diabetes mellitus, with patients having t1dm-sensitive human leucocyte antigen being more susceptible even when receiving glucocorticoids. Physicians should be aware that nivolumab could potentially induce t1dm as a critical immune-related adverse event.",
author = "C. Sakaguchi and K. Ashida and S. Yano and K. Ohe and Naoko Wada and N. Hasuzawa and yayoi matsuda and Shohei Sakamoto and Ryuichi Sakamoto and Uchi Hiroshi and Masutaka Furue and M. Nomura and Yoshihiro Ogawa",
year = "2019",
month = "2",
day = "1",
doi = "10.3747/co.26.4130",
language = "English",
volume = "26",
pages = "e115--e118",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "1",

}

TY - JOUR

T1 - A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma

AU - Sakaguchi, C.

AU - Ashida, K.

AU - Yano, S.

AU - Ohe, K.

AU - Wada, Naoko

AU - Hasuzawa, N.

AU - matsuda, yayoi

AU - Sakamoto, Shohei

AU - Sakamoto, Ryuichi

AU - Hiroshi, Uchi

AU - Furue, Masutaka

AU - Nomura, M.

AU - Ogawa, Yoshihiro

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Nivolumab, an anti-PD-1 antibody, is now considered an important therapeutic agent in several advanced malignancies. However, immune-related adverse events such as endocrinopathies have been reported with its use. Thyroid disorder and isolated adrenocorticotropic hormone deficiency have frequently been reported as nivolumab-induced immune-related adverse events. Another endocrinopathy is nivolumab-induced type 1 diabetes mellitus (t1dm), described as diabetes mellitus with rapid onset and complete insulin insufficiency, at times leading to fulminant t1dm. We report the case of a 68-year-old woman who developed pancreatic islet-related autoantibody-negative t1dm, possibly induced by nivolumab, under continuous glucocorticoid administration. She was treated with nivolumab for advanced malignant melanoma, concomitant with 10 mg prednisolone daily for thrombophlebitis tapered to 5 mg after 13 courses of nivolumab therapy. At approximately the 27th course of nivolumab therapy, she showed elevated plasma glucose levels despite preserved insulin secretion. A month later, she developed diabetic ketoacidosis. Her insulin secretion decreased and finally was exhausted. She was diagnosed with acute-onset rather than fulminant t1dm because of a rapidly progressive course to diabetic ketoacidosis during just more than 1 week. She is currently receiving insulin replacement. There has been no recurrence of the melanoma. Thus, nivolumab might induce autoimmune diabetes mellitus, with patients having t1dm-sensitive human leucocyte antigen being more susceptible even when receiving glucocorticoids. Physicians should be aware that nivolumab could potentially induce t1dm as a critical immune-related adverse event.

AB - Nivolumab, an anti-PD-1 antibody, is now considered an important therapeutic agent in several advanced malignancies. However, immune-related adverse events such as endocrinopathies have been reported with its use. Thyroid disorder and isolated adrenocorticotropic hormone deficiency have frequently been reported as nivolumab-induced immune-related adverse events. Another endocrinopathy is nivolumab-induced type 1 diabetes mellitus (t1dm), described as diabetes mellitus with rapid onset and complete insulin insufficiency, at times leading to fulminant t1dm. We report the case of a 68-year-old woman who developed pancreatic islet-related autoantibody-negative t1dm, possibly induced by nivolumab, under continuous glucocorticoid administration. She was treated with nivolumab for advanced malignant melanoma, concomitant with 10 mg prednisolone daily for thrombophlebitis tapered to 5 mg after 13 courses of nivolumab therapy. At approximately the 27th course of nivolumab therapy, she showed elevated plasma glucose levels despite preserved insulin secretion. A month later, she developed diabetic ketoacidosis. Her insulin secretion decreased and finally was exhausted. She was diagnosed with acute-onset rather than fulminant t1dm because of a rapidly progressive course to diabetic ketoacidosis during just more than 1 week. She is currently receiving insulin replacement. There has been no recurrence of the melanoma. Thus, nivolumab might induce autoimmune diabetes mellitus, with patients having t1dm-sensitive human leucocyte antigen being more susceptible even when receiving glucocorticoids. Physicians should be aware that nivolumab could potentially induce t1dm as a critical immune-related adverse event.

UR - http://www.scopus.com/inward/record.url?scp=85062709945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062709945&partnerID=8YFLogxK

U2 - 10.3747/co.26.4130

DO - 10.3747/co.26.4130

M3 - Article

VL - 26

SP - e115-e118

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 1

ER -